Migraine in Children and Adolescents
Clinical trial for children and adolescents (aged 6-17 years) with a history of migraine with and without aura.
Study site: Encore Medical Research
- Migraine
Recruiting
Male/Female
6 - 17 years of age
Compensation Provided
- About the Study
- The purpose of this study is to evaluate how safe and effective the investigational drug ubrogepant is in the acute treatment of migraine in children and adolescents.
- What does the study involve?
- Ubrogepant is approved for the acute treatment of migraine in adults but has not been studied in children 6-17 years of age. The study will include 2 cohorts of participants - PK Cohort for children 6 to 11 years of age and the Main safety and efficacy study for children 6 to 17 years of age. There will also be a possibility for your child to participate in the long-term extension study, after completion of the main safety and efficacy study, where they will receive Ubrogepant for a year.
- Who can participate?
- Your child may qualify for the study if they are between the ages of 6-17 years old, have experienced migraines for at least 6 months, and experienced between 1 and 14 migraine attacks per month.
- Is compensation provided?
- Yes: $1+ for taking part.
Where is the study taking place?
Hollywood
Weston
Boynton Beach
One moment…
About Encore Medical Research
Encore Medical Research has been serving the South Florida Community since 2017 focusing on phases II through IV clinical trials. Our goal is to provide the highest standard of care to our patients while delivering unmatched performance in our research operations.